News | Treatment Planning | July 21, 2017

Eight Proton Therapy Centers Worldwide Adopt RayStation for Treatment Planning

Latest version of RayStation includes proton-specific features including fast Monte Carlo pencil beam scanning optimization and dose calculation

Eight Proton Therapy Centers Worldwide Adopt RayStation for Treatment Planning

July 21, 2017 — RaySearch Laboratories reported that eight additional proton therapy centers worldwide have recently chosen RayStation as their treatment planning system.

Six of the orders were received in June 2017:

  • The Children’s Cancer Hospital Foundation (Cairo, Egypt);
  • Hospital Quirónsalud (Madrid, Spain);
  • Mayo Clinic Hospital (Phoenix, Ariz.);
  • ZON-PTC (Maastricht, Netherlands);
  • MedStar Georgetown University Hospital (Washington, D.C.); and
  • The Johns Hopkins Medicine proton center at Sibley Memorial Hospital (Washington, D.C.)

RayStation was also recently selected by Tata Memorial Center in Mumbai, one of India’s first proton therapy facilities, and PLA General Hospital in Beijing, China. A total of 35 proton centers have purchased RayStation so far, and this constitutes more than half of the existing proton centers in the world, according to the company.

These eight centers represent a variety of hospital environments and machine types. RayStation will be used together with the IBA Proteus Plus and Proteus One systems, Mevion systems with Hyperscan and Hitachi ProBeat systems.

The centers will receive the latest version of RayStation, which includes features such as fast Monte Carlo pencil beam scanning (PBS) optimization and dose calculation, use of PBS with apertures, and robust optimization/4D-CT (computed tomography) optimization for proton and carbon ion planning. All purchases include both clinical and research licenses.

RayStation has a wide range of features of value to researchers at academic centers. A few examples are LET and RBE calculations for proton and carbon PBS planning, interplay evaluation from machine delivery log files, positron emission tomography (PET)-based range verification, proton and carbon planning on virtual cone beam computed tomography (CBCT) images and small animal X-ray irradiator planning.

The clinical and research configurations of RayStation will be on show at the upcoming American Association of Physicists in Medicine (AAPM) Annual Meeting, July 30-Aug. 2 in Denver.

For more information: www.raysearchlabs.com

Related Content

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline).

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline). See more figures from this study.

Feature | Radiation Therapy | September 28, 2021
September 28, 2021 — New research from Washington University School of Medicine in St.
The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 billion in 2021 at a compound annual growth rate (CAGR) of 7.5%

Varian's Ethos artificial intelligence radiotherapy device.

News | Radiation Oncology | September 28, 2021
September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.

Getty Images

News | Prostate Cancer | September 24, 2021
September 24, 2021 — Scientists have identified two subtypes of metastatic...
The "Global Surface Guided Radiation Therapy (SGRT) Devices Market, By Device Type (Portable v/s Fixed), By Application (Breast Cancer, Head & Neck Cancer, Abdominal & Pelvic Cancer, Dermatology, Others), By End User, By Region, Competition Forecast & Opportunities, 2026" report

Image courtesy of Varian

News | Radiation Therapy | September 24, 2021
September 24, 2021 — The ...
The National Cancer Institute announced that Virginia Commonwealth University Massey Cancer Center, Medical University of South Carolina Hollings Cancer Center and City of Hope Comprehensive Cancer Center secured a highly competitive Specialized Program of Research Excellence (SPORE) grant that aims to address lung cancer racial disparities through precision medicine, targeted smoking cessation programs and community outreach.

VCU Massey Cancer Center director and SPORE principal investigator Dr. Robert Winn explains how this grant will help combat racial inequities in lung cancer. Image courtesy of VCU Massey Cancer Center

News | Lung Imaging | September 23, 2021
September 23, 2021 — The National Cancer Institute announced tha
The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.